---
title: "Camp4 wins Australian clearance for Phase 1/2 CMP-002 trial in SYNGAP1-related disorder"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293921311.md"
description: "Camp4 Therapeutics received Australian TGA clearance to initiate a Phase 1/2 first-in-human trial of CMP-002 for SYNGAP1-related disorder. This regulatory approval triggers eligibility for up to USD 50 million in additional private placement proceeds under a September 9, 2025 agreement. The closing of these funds is expected within five business days, subject to customary conditions."
datetime: "2026-07-27T11:06:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293921311.md)
  - [en](https://longbridge.com/en/news/293921311.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293921311.md)
---

# Camp4 wins Australian clearance for Phase 1/2 CMP-002 trial in SYNGAP1-related disorder

-   Camp4 Therapeutics won Australian TGA clearance to start a Phase 1⁄2 first-in-human trial of CMP-002 for SYNGAP1-related disorder. \* The clearance triggers eligibility for up to USD 50 million in additional private placement proceeds under a September 9, 2025 agreement. \* Closing is expected within five business days, subject to customary conditions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Camp4 Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-049661), on July 27, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [CAMP.US](https://longbridge.com/en/quote/CAMP.US.md)

## Related News & Research

- [CAMP4 Therapeutics Q2 loss per share misses estimates on non-cash derivative charge](https://longbridge.com/en/news/295841350.md)
- [Camp4 Therapeutics closes second tranche of private placement, raises $50.1 million](https://longbridge.com/en/news/294813210.md)
- [CAMP4 wins Australia clearance to start Phase 1/2 trial of CMP-002 in SYNGAP1 disorder](https://longbridge.com/en/news/294149424.md)
- [Elicera corrects CARMA update, says 2 of 3 prior CAR T patients show tumor response, not all 3](https://longbridge.com/en/news/295928409.md)
- [Camp4 net loss widens to $33.5 million in Q2 FY26](https://longbridge.com/en/news/295842670.md)